Hormonal profiles and metabolic changes in women diagnosed with concomitant Hashimoto’s thyroiditis and polycystic ovary syndrome via sonography
DOI:
https://doi.org/10.15584/ejcem.2025.3.12Keywords:
Hashimoto’s thyroiditis, polycystic ovarian syndrome, sonographic changesAbstract
Introduction and aim. Women with both Hashimoto’s thyroiditis (HT) and polycystic ovary syndrome (PCOS) often experience hormonal imbalances and metabolic changes. We investigated the correlation between sonographic changes and hormonal abnormalities in women with Hashimoto’s thyroiditis and PCOS.
Material and methods. A case-control study including 150 women with PCOS and Hashimoto’s thyroiditis, and 50 healthy women as a control group, was conducted at Al-Habobbi Teaching Hospital from 7/1/2023 to 7/10/2024. Lipid, blood sugar, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, testosterone, and thyroid hormones were assessed, the groups had similar mean ages and smoking rates.
Results. When the case group was compared with the control group, significant hormonal and metabolic differences were observed. Specifically, levels of LH were significantly higher in the case group (14.68±1.21 vs. 3.31±1.03 mIU/mL, p=0.001), as were levels of FSH (14.85±1.07 vs. 5.26±0.51 mIU/mL, p<0.001), prolactin (28.90±1.34 vs. 7.02±1.16 ng/dL, p<0.001), and testosterone (57.71±2.61 vs. 12.41±2.27 ng/dL, p<0.001). In terms of lipid profile, the case group showed elevated total cholesterol (229.93±14.61 vs. 134.51±9.38 mg/dL, p<0.001), triglycerides (287.78±41.43 vs. 128.04±10.20 mg/dL, p<0.001), low-density lipoprotein (LDL) (136.98±20.02 vs. 58.67±11.45 mg/dL, p<0.001), and very low-density lipoprotein (VLDL) (57.55±8.28 vs. 25.60±2.04 mg/dL, p<0.001), while levels of high-density lipoprotein (HDL) were significantly lower (35.39±3.54 vs. 50.23±4.55 mg/dL, p<0.001). Regarding thyroid function, thyroxine (T4) levels were significantly reduced in the case group (9.80±0.77 vs. 15.02±1.25, p<0.001), while thyroid-stimulating hormone levels were elevated (6.25±1.10 vs. 2.17±0.74 μIU/mL, p<0.001).
Conclusion. These findings suggest a potential complex interaction between the thyroid and reproductive glands, which may influence the pathogenesis and metabolic effects of these endocrine disorders. However, the individual and combined effects require further detailed investigation.
Downloads
References
Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. doi: 10.1038/nrdp.2016.57
Qassim M, Sarmad, Mohsen AK, Jalil IS. Assessing the prevalence of bacterial vaginosis among infertile women in Thi-Qar Province, Iraq. Infect Epidemiol Microbiol. 2024;10(4):287-296.
Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25. doi: 10.1016/j.fertnstert.2003.10.004
Gaberscek S, Zaletel K, Schwetz V, Pieber T, Obermayer-Pietsch B, Lerchbaum E. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol. 2015;172:R9-R21. doi: 10.1530/EJE-14-0295
Zhao H, Zhang Y, Ye J, et al. A comparative study on insulin secretion, insulin resistance, and thyroid function in patients with polycystic ovary syndrome with and without Hashimoto’s thyroiditis. Diabetes Metab Syndr Obes. 2021;14:1817-1821. doi: 10.2147/DMSO.S300015
McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42:252-265. doi: 10.1007/s12020-012-9703-2
Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13:391-397. doi: 10.1016/j.autrev.2014.01.007
Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661-672. doi: 10.1002/hep.21146
Ahmed SA, Hissong BD, Verthelyi D, et al. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect. 1999;107:681-686.
Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-3082.
Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev. 2014;94(2):355-382.
Karadayı Ataş P. Exploring the molecular interaction of PCOS and endometrial carcinoma through novel hyperparameter-optimized ensemble clustering approaches. Mathematics. 2024;12(2):295. doi: 10.3390/math12020295
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15. doi: 10.1016/j.fertnstert.2016.05.003
Lateef D, Nasser N, Mohsein O. The relationships between apelin, vaspin and thyroid hormone levels in obese diabetic and non-diabetic women. J Exp Clin Med. 2024;41(2):239-245. doi: 10.52142/omujecm.41.2.3
Ghosh H, Rai S, Manzar MD, et al. Differential expression and interaction of melatonin and thyroid hormone receptors with estrogen receptor α improve ovarian functions in letrozole-induced rat polycystic ovary syndrome. Life Sci. 2022;295:120086. doi: 10.1016/j.lfs.2021.120086
Ataş PK. A novel hybrid model to predict concomitant diseases for Hashimoto’s thyroiditis. BMC Bioinformatics. 2023;24:319. doi: 10.1186/s12859-023-05443-5
Mohsein OA, Thuwaini MM, Salman HK. The relationship between leptin, thyroid hormone, and insulin resistance in obese diabetic patients. Cent Asian J Med Nat Sci. 2023;4(3):518-523.
Cai J, Shen Y, Zhao L, et al. High thyroid-stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Front Endocrinol (Lausanne). 2019;10:222. doi: 10.3389/fendo.2019.00222
Serin AN, Arduc A, Dogan BA, et al. Hashimoto’s thyroiditis worsens ovaries in polycystic ovary syndrome patients compared to Anti-Müllerian hormone levels. BMC Endocr Disord. 2021;21:1-8. doi: 10.1186/s12902-021-00706-9
Arduc A, Dogan BA, Bilgec M, et al. High prevalence of Hashimoto’s thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role? Endocr Res. 2015;40(4):204-210. doi: 10.3109/07435800.2015.1015730
Ho CW, Chang YC, Chen YT, et al. Hashimoto’s thyroiditis might increase polycystic ovary syndrome and associated comorbidities risks in Asia. Ann Transl Med. 2020;8(11):765. doi: 10.21037/atm-19-4763
Kamińska W, Kaczmarek J, Sikora M, et al. Lifestyle intervention towards Mediterranean Diet, physical activity adherence and anthropometric parameters in normal weight women with polycystic ovary syndrome or Hashimoto’s thyroiditis—preliminary study. Ann Agric Environ Med. 2023;30(1):111-117. doi: 10.26444/aaem/159156
Garelli S, Sbrana E, Martinetti M, et al. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):248-251. doi: 10.1016/j.ejogrb.2013.03.003
Mukherjee P, Singla R, Kaur G, et al. The impact of polycystic ovary syndrome (PCOS) on the risk of developing ovarian cancer and thyroid disorders: a comprehensive review. Endocr Metab Immune Disord Drug Targets. 2024;24(5):562-572. doi: 10.2174/0118715303266512231 103075551
Novais JdSM, Ribeiro GR, Rodrigues FC, et al. Polycystic ovary syndrome and chronic autoimmune thyroiditis. Gynecol Endocrinol. 2015;31(1):48-51. doi: 10.3109/09513590.2014.958990
Janssen OE, Karamitsos D, Lindner K, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150(3):363-369. doi: 10.1530/eje.0.1500363
Cai J, Shen Y, Zhao L, et al. High thyroid stimulating hormone level is associated with hyperandrogenism in euthyroid polycystic ovary syndrome (PCOS) women, independent of age, BMI, and thyroid autoimmunity: a cross-sectional analysis. Front Endocrinol (Lausanne). 2019;10:222. doi: 10.3389/fendo.2019.00222
Zhao H, Zhang Y, Ye J, et al. A comparative study on insulin secretion, insulin resistance and thyroid function in patients with polycystic ovary syndrome with and without Hashimoto’s thyroiditis. Diabetes Metab Syndr Obes. 2021;14:1817-1821. doi: 10.2147/DMSO.S300015
Kachuei M, Koushki M, Hashemi S, et al. Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Arch Gynecol Obstet. 2012;285:853-856. doi: 10.1007/s00404-011-2040-5
Arduc A, Dogan BA, Bilgec M, et al. High prevalence of Hashimoto’s thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role? Endocrine Res. 2015;40(4):204-210. doi: 10.3109/07435800.2015.1015730
Fan H, Zhang H, Li Y, et al. The role of the thyroid in polycystic ovary syndrome. Front Endocrinol. 2023;14: 1242050. doi: 10.3389/fendo.2023.1242050 doi: 10.3389/fendo.2023.1242050
Palomba S, De Wilde MA, Falbo A, et al. Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature. Front Endocrinol. 2023;14:1251866. doi: 10.3389/fendo.2023.1251866
Qassim Mohammad S, Khazal Mohsen A, Saleh Jalil I, Akram mohsein O. Assessing the Prevalence of Bacterial Vaginosis among Infertile Women in Thi- Qar Province, Iraq. IEM. 2024; 10(4):287-296. doi: 10.61186/iem.10.4.287
Lee HJ, Lee SH, Kim SW, et al. Is there association between thyroid stimulating hormone levels and the four phenotypes in polycystic ovary syndrome? Ginekol Pol. 2023;94(3):203-210. doi: 10.5603/GP.a2021.0239
Batóg G, Stojanović S, Górka A, et al. The interplay of oxidative stress and immune dysfunction in Hashimoto’s thyroiditis and polycystic ovary syndrome: a comprehensive review. Front Immunol. 2023;14:1211231. doi: 10.3389/fimmu.2023.1211231
Davoudi Z, Shariati L, Naderi M, et al. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management. Acta Bio Medica. 2021;92(5):e2021418. doi: 10.23750/abm.v92i5.9866
Elnour AAA, Javed M, Elkhier MKS. Comparison of prolactin, follicle-stimulating hormone, luteinizing hormone, estradiol, thyroid-stimulating hormone, free thyroxine and body mass index between infertile and fertile Saudi women. Obstet Gynecol Int J. 2021;12(2):119-122.
Ma M, Wang S, Zhang Y, et al. The imbalance in Th17 and Treg cells in polycystic ovarian syndrome patients with autoimmune thyroiditis. Immunol Investig. 2022;51(5):1170-1181. doi: 10.1080/08820139.2021.1915329
Kim JJ, Kang J, Kim S, et al. Thyroid autoimmunity markers in women with polycystic ovary syndrome and controls. Hum Fertil. 2022;25(1):128-134. doi: 10.1080/14647273.2019.1709668
Abdul-Ameer F, Al-Mashhadani F, Al-Baldawi A, et al. The relationship between serum CTRP-5, C3a/desArg, and complement-C3 levels and hypothyroidism in women with polycystic ovary syndrome. BMC Endocr Disord. 2024;24:272. doi: 10.1186/s12902-024-01801-3
Elslimani A-Z, Elhasi M, Elmhdwi MF. The relation between hypothyroidism and polycystic ovary syndrome. J Pharm Appl Chem. 2016;2(3):35-38.
Shekarian A, Mazaheri-Tehrani S, Shekarian S, Pourbazargan M. Prevalence of subclinical hypothyroidism in polycystic ovary syndrome and its impact on insulin resistance: a systematic review and meta-analysis. BMC Endocr Disord. 2025;25(1):75. doi: 10.1186/s12902-025-01896-2
Gaberšček S, Bavec M, Zaletel K, et al. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol. 2015;172(1):R9-R21.
Du D, Li X. The relationship between thyroiditis and po- lycystic ovary syndrome: a meta-analysis. Int J Clin Exp Med. 2013;6(10):880-885.
Romitti M, Pantoja JP, Orozco A, et al. Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis. Endocr Connect. 2018;7(11):1158-1167. doi: 10.1530/EC-18-0309
Shanmugham D, Natarajan S, Karthik A. Prevalence of thyroid dysfunction in patients with polycystic ovarian syndrome: A cross sectional study. Int J Reprod Contracept Obstet Gynecol. 2018;7:3055-3059.
Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica. 2016;2016: 4071735. doi: 10.1155/2016/4071735
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
